Table 1 Comparisons between cases and controls in terms of Clinical characteristics using Student’s T-test, Mann Whitney, or odds ratio
Clinical characteristics | Controls (n = 248) Median (25th–75th percentile), mean ± SD or n (%) | Cases (n = 250) Median (25th–75th percentile), mean ± SD or n (%) | z/t/OR | P-value |
|---|---|---|---|---|
Age (year) | 51.0 ± 12.6 | 52.6 ± 12.7 | − 1.31 | 0.190 |
Females | 223 (89.9%) | 211 (84.4%) | 1.65 | 0.081 |
Duration of RA disease (year) | 5.0 (3.0–10.0) | |||
Tender joint count | 4.0 (0.0–13.0) | |||
Swollen joint count | 3.0 (0.0–11.0) | |||
VAS | 70.0 (0.0–100.0) | |||
DAS-28-ESR | 4.9 (1.9–6.6) | |||
Laboratory finding | ||||
ESR (mm/h) | 10.0 (6.0–14.2) | 18.5 (10.0–41.0) | − 8.9 | < 0.001 |
CRP (mg/l) | 3.0 (2.5–4.0) | 5.0 (2.0–18.0) | − 6.6 | < 0.001 |
TSH (mIU/L) | 2.3 ± 2.4 | 2.9 ± 2.9 | − 2.3 | 0.024 |
FT3 (pg/mL) | 3.1 ± 1.3 | 3.9 ± 1.6 | − 5.9 | < 0.001 |
FT4 (ng/dl) | 1.0 (0.9–1.3) | 1.2 (1.0–1.6) | − 6.0 | < 0.001 |
Anti-TPO (IU/ml) | 8.9 (5.0–25.0) | 17.3 (6.4–157.0) | − 4.6 | < 0.001 |
Anti-CCP (U/ml) | 15.9 (2.2–185.5) | |||
Anti-MCV (U/ml) | 28.0 (10.0–311.5) | |||
RF positive | 112 (45.2%) | |||
RA Medications | ||||
Prednisolone | 228 (91.2%) | |||
Methotrexate | 222 (88.8%) | |||
Hydroxychloroquine | 151 (60.4%) | |||
Sulfasalazine | 62 (24.8%) | |||
Leflunomide | 61 (24.4%) | |||
Etanercept | 7 (2.8%) | |||
Adalimumab | 4 (1.6%) |